University of Miami

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Miami sits in the top decile of US sponsors by registered trial count (#46 of 15,742 sponsors by registered trial count).

721 total trials 145 currently recruiting 430 completed early-phase tilt top decile by trial count

University of Miami: 721 sponsored US clinical trials, 145 recruiting.

University of Miami sponsors 721 registered US clinical trials on ClinicalTrials.gov, 145 of them currently recruiting, and 430 completed. 79 of these trials are in Phase 3-4 (later-stage) and 134 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 10 trials.

Top-decile sponsor footprint

University of Miami ranks in the top decile of sponsors by registered trial count (#46 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 48/100

430 of 515 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

721 total, page 1 of 15

RECRUITING Phase 2

Intralesional Chemotherapy (IC): Cisplatin + Epinephrine

NCT07392580

RECRUITING NA

Fasting InTervention for Endometrial Cancer

NCT07622901

RECRUITING NA

Remotely-Delivered Cognitive Behavioral Stress Management for Breast Cancer (R-CBSM)

NCT07502352

RECRUITING NA

Self-applied taVNS for CIPN

NCT07596030

RECRUITING Phase 4

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

NCT06412120

RECRUITING NA

Haptics in Virtual Reality

NCT07209228

RECRUITING Phase 2

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

NCT07594015

RECRUITING NA

Relationship Enhancement Digital Game

NCT07170553

RECRUITING Phase 2

Doxycycline Use in Post-Operative Seromas

NCT07498010

RECRUITING NA

Implementing Depression and Adherence Treatment

NCT07032363

RECRUITING NA

Project Independence

NCT07572110

RECRUITING NA

Cuneiform Nucleus (CnF) Deep Brain Stimulation for Gait Facilitation Following Spinal Cord Injury

NCT07109804

RECRUITING NA

Prehabilitation Protocol for Head and Neck Cancer Patients

NCT07318220

RECRUITING Phase 4

Ventilation and Perfusion in Asthmatics

NCT07426458

RECRUITING NA

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

NCT07446777

RECRUITING NA

Food Intake and Thermogenesis in High Spinal Cord Injury

NCT07103993

RECRUITING NA

Binaural Beats for Postoperative Pain and Anxiety Reduction

NCT07437469

RECRUITING NA

The GLUCID Study: Effect of Alcohol Reduction and Probiotic Interventions on Cognition and Brain Glucose Metabolism in Normal Aging Adults Who Are High-Risk Alcohol Drinkers

NCT07415707

RECRUITING Phase 4

Improving Postoperative Recovery: A Study of Multimodal Perineal Analgesia Protocol (MPAP) After Vaginal Surgery

NCT07401134

RECRUITING Phase 4

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

NCT07217678

RECRUITING NA

Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patients

NCT07359911

RECRUITING Phase 1

Methylene Blue in Total Knee Arthroplasty (TKA)

NCT07324954

RECRUITING NA

Low Versus High Load Training and Parkinson's Disease

NCT07378813

RECRUITING NA

Power Training Progression Methods

NCT07378826

RECRUITING Phase 2

Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

NCT06919939

RECRUITING Phase 2

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

NCT06902246

RECRUITING NA

Passive Neurosensory Reintegration Training as a Tool to Augment Mild Traumatic Brain Injury

NCT07356167

RECRUITING NA

Gut-Brain Neural Coupling in Spinal Cord Injury

NCT07052344

RECRUITING NA

Effects of an Exercise Program on Reaction Time and Mouse Accuracy in Recreational Video Game Players

NCT06512675

RECRUITING NA

Fostering Oral Chemotherapy Understanding and Safety (FOCUS) Study

NCT06952790

RECRUITING Phase 2

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

NCT06997081

RECRUITING NA

Understanding Decentralized Trial Engagement and Clinical Impediments Through Digital Efforts (UDECIDE) Among Unrepresented Groups With Poor Cardiovascular and Cardiometabolic Health

NCT06587204

RECRUITING Phase 2

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

NCT07096362

RECRUITING NA

Periodization and Parkinson's Disease

NCT07141849

RECRUITING NA

Power or Plyometric Training in Older Adults

NCT06821321

RECRUITING NA

Preoperative Comprehensive Geriatric Assessment (CGA) and Postoperative Delirium

NCT07059585

RECRUITING Phase 2

BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

NCT07002216

RECRUITING NA

Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)

NCT06730555

RECRUITING Phase 1

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

NCT05956821

RECRUITING Phase 1

Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI

NCT05630235

RECRUITING Phase 2

ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

NCT06902272

RECRUITING Phase 2

Adjuvant Quisinostat in High-Risk Uveal Melanoma

NCT06932757

RECRUITING Phase 2

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

NCT06663722

RECRUITING Phase 4

Magnesium-L-Threonate for Sleep Quality Post-Arthroplasty

NCT06902285

RECRUITING NA

Metabolic Impact and Compliance of Controlled, Varying, Mediterranean Diets in Pre-Surgical Prostate Cancer Populations (PROVISIONS)

NCT06487507

RECRUITING Phase 1

STARLITE for Unresectable High-Grade Gliomas

NCT06428045

RECRUITING NA

The Test-to-PrEP Study

NCT06927856

RECRUITING NA

Florida Community-Engaged Research Alliance (FL-CEAL)

NCT06829485

RECRUITING Phase 4

Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

NCT06774079

RECRUITING NA

Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)

NCT06784323

Page 1 of 15 Next →

Phase Distribution

PhaseTrial count
Phase 1 48
Phase 2 86
Phase 3 18
Phase 4 61

What is open in the University of Miami pipeline

145 recruiting of 721 indexed (20% open); 430 completed (60%).

Phase mix: 79 late (III/IV) vs 134 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Miami: open-pipeline peers nationwide

Peers matched on 721 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

University of Miami sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 5%10%15%20%25% Total trials Recruiting share University of MiamiSanofiThe University of Texas Health Science Center, HoustonIcahn School of Medicine at Mount SinaiWeill Medical College of Cornell UniversityUniversity of California, IrvineEndeavor HealthAcera SurgicalAlign Technology
University of Miami sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Miami sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 721 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

What to do with this University of Miami page

721 registered trials is a research-attention snapshot, not an endorsement of University of Miami or any single study.

  • 145 of University of Miami's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition University of Miami studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Miami pipeline card: 721 registered trials from official public datasets.Report a data error.